Science

Partnership
Building strong and lasting partnership is essential to the success of our business and our customers.  We pursue innovation through both internal R&D and external collaboration.  Partnerships and collaborations are critical to evolving our portfolio and driving our long-term sustainability.

● Out-licensing: we seek partners with global R&D and commercial expertise to help realize the full potential of our innovative assets on a global or regional level.
● In-licensing: we are constantly seeking and evaluating both late clinical stage assets that may complement our in-house pipeline and first-in-class compounds with breakthrough potential.
● Strategic collaboration: we are open to working with any entities, industry or academic and big or small, and new ideas of any kind with potential to help our patients and maximize the power of our portfolio.

In July 2019, we entered into an exclusive license agreement with X4 Pharmaceuticals, Inc. (“X4”) and obtained the rights for the development, manufacturing and commercialization of the licensed compound ABSK081 (mavorixafor), which was formerly known as X4P-001, collectively with any product containing such licensed compound (the “X4 Product”) in the licensed territory of mainland China, Taiwan, Hong Kong and Macau.

In October 2019, we entered into a combination therapy development agreement with Shanghai Junshi Biomedical Technology Co., Ltd. to develop a combination therapy for the treatment of triple-negative breast cancer (TNBC).

In November 2019, we entered into an exclusive license agreement with AstraZeneca and obtained the global rights for the development, manufacturing and commercialization of ABSK091 (AZD4547).

For more information on collaboration
with Abbisko please contact our business development team at

Tel:(+86) 021-68912098

E-Mail:Public@abbisko.com Bd@abbisko.com

Copyright © 2021 All rights reserved:Abbisko Therapeautics     沪ICP备17056565号-1